
Opinion|Videos|October 17, 2024
Advocacy Groups and Integration of Wellness Strategies into Treatment for Parkinson’s Disease
Author(s)Stuart H. Isaacson, MD, FAAN
Key Takeaways
- Integrating nutrition and exercise into PD treatment plans can improve patient outcomes and quality of life.
- Encouraging patient adherence to wellness habits and pharmacological therapy is essential for effective PD management.
Dr. Isaacson discusses how physicians can effectively integrate wellness strategies such as nutrition and exercise into treatment plans for Parkinson's disease (PD), encourage patient adherence to these habits alongside pharmacological therapy, and leverage advocacy groups as vital resources for both patients and health care professionals (HCPs) in navigating wellness and care management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How should physicians integrate wellness strategies, such as nutrition and exercise, into the treatment plans for patients with PD?
- What should HCPs do to encourage patients to adopt and maintain wellness habits and comply with pharmacological therapy for PD?
- What is the role of advocacy groups for patients in navigating PD, especially in adopting and encouraging wellness habits?
- How can HCPs leverage these resources in their practices?
- Are there any advocacy groups that are focused on HCPs in PD?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis
2
Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis
3
Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers
4
CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis
5






